含有格利克拉的塑料纳米纤维:增强生物可用性和抗糖尿病功效
Shimaa Mazyed1, Soha M El-Masry1, Haidy Abbas1
1Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
Drug development and industrial pharmacy
|March 17, 2025
概括
装有gliclazide (GCZ) 的Spanlastics纳米纤维 (SNVs) 改善了口服生物可用性和抗糖尿病作用. 优化的SNVs与自由的GCZ相比显示了增强的药理动力学和药理动力学概况.
科学领域:
- 制药科学 制药科学
- 纳米技术纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 格利克拉 (GCZ) 是一种口服抗糖尿病药物,生物利用性有限.
- 纳米管状药物递送系统有可能提高药物的疗效.
研究的目的:
- 为了制定和表征带有gliclazide (GCZ) 的spanlastics纳米纤维 (SNVs).
- 评估加载GCZ的SNVs的增强口服生物可用性和抗糖尿病作用.
主要方法:
- 使用乙醇注射方法准备SNV,使用不同的跨度和边缘激活器类型.
- 一个23的因数设计优化了配方.
- 在体外释放药物,体内药理动力学和药理动力学被评估.
主要成果:
- 优化的配方 (F6) 呈现出具有高捕获效率 (95.1%) 的球形粒子.
- 实验室释放显示药物持续释放超过4小时.
- 在体内研究表明,与自由GCZ相比,Cmax显著增加 (12.93±1.34),葡萄糖减少改善 (58.31%MR).
结论:
- 装有GCZ的SNV显著提高了口服生物可用性和抗糖尿病活性.
- 开发的SNVs为改善gliclazide治疗提供了一个有希望的方法.
相关概念视频
Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281
Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K


